Page last updated: 2024-09-04

ezetimibe and fenofibrate

ezetimibe has been researched along with fenofibrate in 56 studies

Compound Research Comparison

Studies
(ezetimibe)
Trials
(ezetimibe)
Recent Studies (post-2010)
(ezetimibe)
Studies
(fenofibrate)
Trials
(fenofibrate)
Recent Studies (post-2010) (fenofibrate)
2,4845631,4653,0585291,354

Protein Interaction Comparison

ProteinTaxonomyezetimibe (IC50)fenofibrate (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)2.371
Adenosine receptor A3Homo sapiens (human)5.701
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)5.701
5-hydroxytryptamine receptor 2AHomo sapiens (human)2.118
5-hydroxytryptamine receptor 2CHomo sapiens (human)2.371
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)5.701
Sodium-dependent dopamine transporter Homo sapiens (human)8.633
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)1
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)5.1

Research

Studies (56)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's21 (37.50)29.6817
2010's32 (57.14)24.3611
2020's3 (5.36)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Császár, A; Márk, L1
Cottrell, DA; Falko, JM; Marshall, BJ1
Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP1
Davies, MJ; Farnier, M; Freeman, MW; Gumbiner, B; Macdonell, G; Mitchel, YB; Perevozskaya, I1
Stalenhoef, AF1
Borja, J1
Giral, P; Jublanc, C; Turpin, G1
Bays, HE; Carlson, G; Davies, MJ; Farnier, M; Gumbiner, B; Lo, KW; McKenney, JM; Mitchel, YB; Perevozkaya, I1
Achari, R; Burt, DA; Chira, T; Edeki, T; Gustavson, LE; Kelly, MT; Rieser, MJ; Schweitzer, SM; Yannicelli, HD1
Cimadevilla, C; Guillausseau, PJ; Meas, T; Mouly, S; Timsit, J1
Chun, P; Chung, S; Moon, YS1
Farnier, M1
Elisaf, M; Gazi, IF; Kalogirou, M; Kostapanos, M; Saougos, VG; Tambaki, AP; Tselepis, AD; Wolfert, RL1
Chrysohoou, C; Singh, S1
Elisaf, MS; Florentin, M; Liberopoulos, EN; Mikhailidis, DP1
Davies, MJ; Farnier, M; Gumbiner, B; Macdonell, G; Musliner, TA; Perevozskaya, I; Tribble, DL1
Farnier, M; Kush, D; Mitchel, YB; Perevozskaya, I; Taggart, WV1
Robinson, JG1
Ansquer, JC; Bekaert, I; Guy, M; Hanefeld, M; Simon, A1
Abletshauser, C; Geisen, U; Hoffmann, MM; Odünc, N; Pütz, G; Schäfer, G; Schewe, T; Siegel, E; Winkler, K1
Visseren, FL; Westerink, J1
Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A1
Day, A; Kumar, SS; LaHaye, SA; Lahey, KA1
Dunn, FL1
Phillips, W; Schaefer, S1
Drakopoulou, M; Skoumas, I; Stefanadis, C; Toutouzas, K1
Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC1
Inui, K; Iwayanagi, Y; Suzuki, H; Takada, T; Terada, T; Tomura, F; Yamanashi, Y1
Bays, HE; Gumbiner, B; Macdonell, G; Shah, A; Taggart, WV1
Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS1
Cao, G; Konrad, RJ; Troutt, JS1
Kishimoto, M; Noda, M; Okamoto, M; Osame, K; Sugiyama, T; Takarabe, D1
Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Shah, A1
Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A1
Bandgar, TR; Faruqui, AA1
Prasad, V; Vandross, A1
Hellerstein, M; Turner, S1
Angus, PW; Ekinci, EI; Gow, PJ; Jones, RM; O'Brien, RC; Page, MM1
Annoni, F; Caputo, S; Cremona, AM; Grandi, AM; Grossi, P; Guasti, L; Marchesi, C; Maresca, AM; Nicolini, E; Rizzi, L1
Brunet, A; Cannon, CP; DiCioccio, AT; Hanotin, C; Paehler, T; Pinquier, JL; Poitiers, F; Rey, J; Sasiela, WJ; Surks, HK1
Kono, S; Nakaya, N; Oikawa, S; Sasaki, J; Yamashita, S1
Baccara-Dinet, MT; Civeira, F; Farnier, M; Gaudet, D; Guyton, JR; Lecorps, G; Lepor, N; Manvelian, G; Stroes, E; Watts, GF1
Gao, X; Jacobs, RL; Kassiri, Z; Lingrell, S; Takawale, A; van der Veen, JN; Vance, DE1
Arimura, A; Arimura, H; Deguchi, T; Hashiguchi, H; Kikuti, A; Kurano, M; Nishio, Y; Shinnakasu, A; Yamamoto, K1
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N1
Cao, JT; Chen, K; Fan, YQ; Gao, L; Wang, CQ; Wang, Y; Xie, YS; Xu, ZJ; Yin, ZF; Zhang, HL1
Hsiung, JT; Kleine, CE; Moradi, H; Park, C; Soohoo, M; Streja, DA; Streja, E1
Liu, F; Shu, M; Tang, M; Wu, X; Xia, P; Zhan, S1
Banach, M; Katsiki, N; Mikhailidis, DP1
Chmiel, K; Jurkiewicz, K; Knapik-Kowalczuk, J; Kramarczyk, D; Paluch, M1
Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C1
Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T1

Reviews

16 review(s) available for ezetimibe and fenofibrate

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
[Antilipemic agents in combined therapy].
    Orvosi hetilap, 2002, Aug-25, Volume: 143, Issue:34

    Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6

2002
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
    Current opinion in cardiology, 2003, Volume: 18, Issue:4

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fenofibrate; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Particle Size

2003
Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia.
    Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:1

    Topics: Azetidines; Drug Combinations; Drug Synergism; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents

2007
Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:9

    Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias

2007
Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
    Recent patents on cardiovascular drug discovery, 2006, Volume: 1, Issue:1

    Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors

2006
Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia.
    Current medical research and opinion, 2008, Volume: 24, Issue:4

    Topics: Allylamine; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Risk Factors

2008
LDL reduction: how low should we go and is it safe?
    Current cardiology reports, 2008, Volume: 10, Issue:6

    Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Muscular Diseases; Niacin; Risk Factors; Stroke

2008
Management of dyslipidemia in people with type 2 diabetes mellitus.
    Reviews in endocrine & metabolic disorders, 2010, Volume: 11, Issue:1

    Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides

2010
Advancing therapy for hypercholesterolemia.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10

    Topics: Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Niacin

2010
Reverse cholesterol transport fluxes.
    Current opinion in lipidology, 2014, Volume: 25, Issue:1

    Topics: Arthritis, Rheumatoid; Azetidines; Biological Transport; Cholesterol; Ezetimibe; Fenofibrate; Humans; Hypoalphalipoproteinemias

2014
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.
    Internal medicine journal, 2014, Volume: 44, Issue:6

    Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Consanguinity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Liver Transplantation; Male; Pyrroles; Receptors, LDL

2014
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
    Seminars in nephrology, 2018, Volume: 38, Issue:4

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Failure, Chronic; Muscular Diseases; Niacin; PCSK9 Inhibitors; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Renal Dialysis; Renal Insufficiency, Chronic

2018
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    The Cochrane database of systematic reviews, 2018, 11-19, Volume: 11

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Triglycerides

2018
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:16

    Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Renal Insufficiency, Chronic

2019
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
    Current problems in cardiology, 2023, Volume: 48, Issue:8

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; Proprotein Convertases; Secondary Prevention; Subtilisins

2023

Trials

20 trial(s) available for ezetimibe and fenofibrate

ArticleYear
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.
    Current medical research and opinion, 2004, Volume: 20, Issue:8

    Topics: Adult; Azetidines; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pilot Projects; Single-Blind Method; Treatment Outcome

2004
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
    European heart journal, 2005, Volume: 26, Issue:9

    Topics: Adolescent; Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome

2005
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
    Journal of the American College of Cardiology, 2006, Apr-18, Volume: 47, Issue:8

    Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome

2006
Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
    Clinical therapeutics, 2006, Volume: 28, Issue:3

    Topics: Adult; Azetidines; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Glucuronides; Humans; Hypolipidemic Agents; Male; Middle Aged

2006
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:10

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Phospholipases A2; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides

2007
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Metabolism: clinical and experimental, 2008, Volume: 57, Issue:6

    Topics: Adolescent; Adult; Aged; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Particle Size; Triglycerides

2008
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
    Journal of lipid research, 2008, Volume: 49, Issue:12

    Topics: Adult; Aged; Azetidines; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Middle Aged; Simvastatin

2008
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter,
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9, Issue:2

    Topics: Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged

2009
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
    European journal of clinical investigation, 2009, Volume: 39, Issue:6

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Humans; Indoles; Male; Metabolic Syndrome; Middle Aged; Simvastatin; Treatment Outcome

2009
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
    Angiology, 2010, Volume: 61, Issue:4

    Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss

2010
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.
    Lipids in health and disease, 2009, Dec-17, Volume: 8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Demography; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Young Adult

2009
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
    American heart journal, 2010, Volume: 160, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult

2010
Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
    Metabolic syndrome and related disorders, 2011, Volume: 9, Issue:2

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Triglycerides

2011
Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes.
    The journal of medical investigation : JMI, 2011, Volume: 58, Issue:1-2

    Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged

2011
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
    Lipids in health and disease, 2011, Nov-16, Volume: 10

    Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome

2011
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
    Diabetes & vascular disease research, 2012, Volume: 9, Issue:3

    Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome

2012
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
    Journal of the International AIDS Society, 2014, Volume: 17

    Topics: Adult; Anticholesteremic Agents; Azetidines; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Ezetimibe; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome

2014
Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Journal of the American Heart Association, 2016, 06-10, Volume: 5, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Proprotein Convertase 9; Young Adult

2016
Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study.
    Journal of atherosclerosis and thrombosis, 2017, Jan-01, Volume: 24, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Treatment Outcome; Young Adult

2017
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
    Journal of the American Heart Association, 2016, 09-13, Volume: 5, Issue:9

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Combined Modality Therapy; Diet Therapy; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipidemic Agents; Injection Site Reaction; Male; Middle Aged; PCSK9 Inhibitors; Treatment Outcome

2016

Other Studies

20 other study(ies) available for ezetimibe and fenofibrate

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Management of mixed hyperlipidaemia.
    European heart journal, 2005, Volume: 26, Issue:9

    Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents

2005
Ezetimibe coadministered with fenofibrate: some safety questions.
    European heart journal, 2005, Volume: 26, Issue:21

    Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Drug Combinations; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias

2005
[Ezetimibe with statins].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:3 Pt 2

    Topics: Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents

2006
Elevation of CKP induced by ezetimibe in monotherapy: report on two cases.
    Diabetes & metabolism, 2006, Volume: 32, Issue:4

    Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Creatinine; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fenofibrate; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Male; Middle Aged

2006
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
    European journal of clinical investigation, 2010, Volume: 40, Issue:1

    Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hypolipidemic Agents; Indoles; Metabolic Syndrome; Simvastatin

2010
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
    Preventive cardiology, 2010,Spring, Volume: 13, Issue:2

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Middle Aged; Niacin

2010
Human NPC1L1 expression is positively regulated by PPARα.
    Pharmaceutical research, 2011, Volume: 28, Issue:2

    Topics: Azetidines; Cholesterol; Electrophoretic Mobility Shift Assay; Enterocytes; Ezetimibe; Fenofibrate; Gene Expression Regulation; Hep G2 Cells; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Membrane Proteins; Membrane Transport Proteins; Niemann-Pick Diseases; PPAR alpha; PPAR gamma; Protein Binding; Response Elements

2011
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
    Angiology, 2011, Volume: 62, Issue:2

    Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles

2011
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.
    Lipids in health and disease, 2011, Feb-28, Volume: 10

    Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases

2011
Managing dyslipidaemia: evolving role of combination therapy.
    Journal of the Indian Medical Association, 2011, Volume: 109, Issue:8

    Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles

2011
Cardiovascular primary prevention: how high should we set the bar?
    Archives of internal medicine, 2012, Apr-23, Volume: 172, Issue:8

    Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin

2012
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
    Journal of lipid research, 2017, Volume: 58, Issue:4

    Topics: Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Ezetimibe; Fenofibrate; Humans; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Oxidation-Reduction; Phosphatidylethanolamine N-Methyltransferase; Triglycerides

2017
The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes.
    Journal of atherosclerosis and thrombosis, 2017, Jul-01, Volume: 24, Issue:7

    Topics: Anticholesteremic Agents; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prognosis

2017
Reducing CV risk in diabetes: An ADA update.
    The Journal of family practice, 2017, Volume: 66, Issue:5

    Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones

2017
Model design for screening effective Antihyperlipidemic drugs using zebrafish system.
    Pakistan journal of pharmaceutical sciences, 2017, Volume: 30, Issue:5

    Topics: Animals; Atorvastatin; Biomarkers; Cholesterol; Diet, High-Fat; Disease Models, Animal; Drug Discovery; Ezetimibe; Fenofibrate; High-Throughput Screening Assays; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Male; Triglycerides; Zebrafish

2017
Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
    Molecular pharmaceutics, 2021, 09-06, Volume: 18, Issue:9

    Topics: Anticholesteremic Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Compounding; Drug Stability; Drug Storage; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Simvastatin

2021
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
    Clinical drug investigation, 2022, Volume: 42, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine

2022